HT
Therapeutic Areas
Halozyme Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HYLENEX® recombinant | Hypodermoclysis and subcutaneous fluid administration | Approved |
| XYOSTED® CIII | Testosterone replacement therapy | Approved |
Leadership Team at Halozyme Therapeutics
NL
Nicole LaBrosse
Chief Financial Officer
MS
Mark Snyder
Chief Legal Officer
CC
Chase Coffman
President of Hypercon™